ADCs are divided into biomarker-selected (e.g., HER2 and MET overexpression) and biomarker-agnostic types (e.g., TROP2, and HER3), while several antibody drug conjugates are being tested in the specific context of oncogene-addicted NSCLC [261]. This evidence concerns the gene MET and non-small cell lung carcinoma.